Clinical data | |
---|---|
Drug class | Antineoplastic agents |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C33H31F3N6O2 |
Molar mass | 600.646 g·mol−1 |
3D model ( JSmol) | |
| |
|
MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. [1] [2] It is currently in a phase 1/2 clinical trial for the treatment of solid tumors. [3]
Clinical data | |
---|---|
Drug class | Antineoplastic agents |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
PDB ligand | |
Chemical and physical data | |
Formula | C33H31F3N6O2 |
Molar mass | 600.646 g·mol−1 |
3D model ( JSmol) | |
| |
|
MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. [1] [2] It is currently in a phase 1/2 clinical trial for the treatment of solid tumors. [3]